Stock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance

Stock Track04-28 21:57

Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its full-year revenue outlook.

The biopharmaceutical company reported quarterly earnings of $0.27 per share, significantly surpassing the analyst consensus estimate of $0.19. Revenue for the quarter reached $214.3 million, also beating expectations and representing a 56% increase compared to the same period last year.

Investor sentiment was further bolstered by management's decision to raise its 2026 net product revenue guidance for its ARCALYST drug to a range of $930 million to $945 million, up from the previous forecast of $900 million to $920 million. This increased guidance reflects strong confidence in continued sales growth driven by expanding adoption of the treatment for recurrent pericarditis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126449380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126449380","market":"hk","top_or_hot":-1,"title":"Stock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance","media":"Stock Track","content":"<p>Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its full-year revenue outlook.</p><p>The biopharmaceutical company reported quarterly earnings of $0.27 per share, significantly surpassing the analyst consensus estimate of $0.19. Revenue for the quarter reached $214.3 million, also beating expectations and representing a 56% increase compared to the same period last year.</p><p>Investor sentiment was further bolstered by management's decision to raise its 2026 net product revenue guidance for its ARCALYST drug to a range of $930 million to $945 million, up from the previous forecast of $900 million to $920 million. This increased guidance reflects strong confidence in continued sales growth driven by expanding adoption of the treatment for recurrent pericarditis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kiniksa Pharmaceuticals Soars 12.74% on Strong Q1 Earnings Beat and Raised Revenue Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-28 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its full-year revenue outlook.</p><p>The biopharmaceutical company reported quarterly earnings of $0.27 per share, significantly surpassing the analyst consensus estimate of $0.19. Revenue for the quarter reached $214.3 million, also beating expectations and representing a 56% increase compared to the same period last year.</p><p>Investor sentiment was further bolstered by management's decision to raise its 2026 net product revenue guidance for its ARCALYST drug to a range of $930 million to $945 million, up from the previous forecast of $900 million to $920 million. This increased guidance reflects strong confidence in continued sales growth driven by expanding adoption of the treatment for recurrent pericarditis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KNSA","symbol_name":"Kiniksa Pharmaceuticals Ltd.","start_time":0,"source_url":"","article_id":"1126449380","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126449380","pubTimestamp":1777384646,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KNSA":"Kiniksa Pharmaceuticals Ltd."},"translate_title":"个股追踪|Kiniksa Pharmaceuticals飙升12.74%，Q1盈利强劲，营收指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KNSA":1},"content_text":"Kiniksa Pharmaceuticals Ltd. (KNSA) saw its stock price soar 12.74% during intraday trading on Tuesday, following the release of its first-quarter financial results and an upward revision to its full-year revenue outlook.The biopharmaceutical company reported quarterly earnings of $0.27 per share, significantly surpassing the analyst consensus estimate of $0.19. Revenue for the quarter reached $214.3 million, also beating expectations and representing a 56% increase compared to the same period last year.Investor sentiment was further bolstered by management's decision to raise its 2026 net product revenue guidance for its ARCALYST drug to a range of $930 million to $945 million, up from the previous forecast of $900 million to $920 million. This increased guidance reflects strong confidence in continued sales growth driven by expanding adoption of the treatment for recurrent pericarditis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126449380","isCrawlerRequest":true}